CLNNW
Clene IncNASDAQ
Key Statistics
Market Cap
$646.98M
P/E Ratio
—
EPS
—
Beta
0.79
52W High
$0.04
52W Low
$0.00
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Clene Inc
Clene Inc., a clinical-stage biopharmaceutical company, focuses on the development of various therapies for neurodegenerative diseases. The company is headquartered in Salt Lake City, Utah.
Fundamentals
| Revenue (TTM) | 214,000 |
| Gross Profit (TTM) | 176,000 |
| EBITDA | $-22.70M |
| Operating Margin | -37653.00% |
| Return on Equity | -1738.00% |
| Return on Assets | -56.20% |
| Revenue/Share (TTM) | $0.02 |
| Book Value | $-1.21 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -82.80% |
| Shares Outstanding | 0 |
| Float | $7.76M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
0.00%
HV 20-Day
0.00%
HV 30-Day
0.00%
HV 60-Day
163.57%
HV Rank
—
Volatility is currently contracting
Data last updated: 4/10/2026